Defense Advanced Research Projects AgencyTagged Content List

Restore and Maintain Warfighter Abilities

Relating to the restoration and optimization of human health

Showing 11 results for Health + Countermeasures RSS
For more than fifty years, researchers have been studying exactly how aspirin affects the human body. Despite thousands of publications on the topic, our understanding is still incomplete.
Over the past several years, DARPA-funded researchers have pioneered RNA vaccine technology, a medical countermeasure against infectious diseases that uses coded genetic constructs to stimulate production of viral proteins in the body, which in turn can trigger a protective antibody response. As a follow-on effort, DARPA funded research into genetic constructs that can directly stimulate production of antibodies in the body
The increasing threat of infectious diseases is intensifying the need for breakthrough technologies and capabilities to protect first responders and equip them with therapeutics that can halt the impact of infectious agents. Current approaches for recent public health emergencies due to infectious diseases have not produced effective preventive or therapeutic solutions in a relevant timescale. Examples from recent outbreaks such as H3N2 (flu), Ebola, and Zika viruses highlight the significant lag in deployment and efficacy of life-saving solutions.
Protection against many common pathogens and environmental stressors is written into our DNA. Our skin responds to sun exposure. Our immune system mounts defenses when we get the flu. Our bodies inherently work to mitigate the potential for harm caused by these health threats. However, these intrinsic responses are not always quick, robust, or appropriate enough to adequately defend us from harm, which is why many people experience sunburn after intense sun exposure or suffer severe symptoms, even death, following exposure to the flu.
February 22, 2017,
Crown Plaza Tysons Corner-McLean
DARPA’s Biological Technologies Office is hosting a Proposers Day meeting to provide information to potential applicants on the structure and objectives of the new Pandemic Prevention Platform (P3) program. P3 aims to develop an integrated, end-to-end platform that uses nucleic acid sequences to halt the spread of viral infections in 60 days or less. Performers will use nucleic-acid-based technologies pioneered by DARPA as a foundation for work to overcome the remaining bottlenecks preventing rapid response to pandemic threats.